Prime Business Africa
Neimeth International Pharmaceuticals Plc generated N5 billion in the first nine months of 2025, surpassing the N3.09 billion turnover recorded in the corresponding period in 2024, representing a 62 percent growth.
The drug maker, in its financial statements for the period ended September 30, 2025, said it spent N2.52 billion on production costs, which is 54 percent increase compared to the N1.64 billion expended last year.
Join our WhatsApp ChannelNeimeth added that gross profit rose to N2.48 billion between January and September 2025, from the N1.45 billion earned in the same period in 2024, indicating a 71 percent increase.
Also, other income grew by 132 percent to N312.35 million between the first quarter and the third quarter (Q3) this year, exceeding the N134.51 million posted in 2024.
In addition, marketing and distribution expenses increased slightly by 6 percent year-on-year, from N412.72 million to N437.44 million, while administrative expenses rose by 67 percent, from N420.06 million to N701.45 million.
The company’s earnings were boosted by a 120 percent increase in operating profit, which was N1.65 billion in the first nine months of this year, compared to the N753.24 million reached in the same period of 2024.
During the period under review, Neimeth said finance cost gulped N1.31 billion between Q1 and Q3, compared to the N442.76 million recorded in the corresponding period last year.
However, despite the 198 percent increase in finance cost, Neimeth was able to squeeze out a 9 percent growth in profit before tax (PAT), which increased to N339.77 million between January and September 2025, from N310.48 million PAT earned in 2024.
Neimeth said it did not pay tax in the first nine months of 2024 and 2025.
For press releases, tip-offs, and corporate information, call 08149575257 (hotline), email: editor@primebusiness.africa and publisher@primebusiness.africa
